Cortifen

Cortifen
Clinical data
Other names	Cortiphen; Kortifen; Fencoron; 11-Deoxycortisol 21-(4-(bis(2-chloroethyl)amino)phenyl)acetate; 11-Desoxy-17α-hydroxy-21-[n-di-2(chlorethyl)aminophenyl acetate]corticosterone
Drug class	Cytostatic antineoplastic agent; Corticosteroid; Glucocorticoid
Identifiers
	IUPAC name [2-[(8R,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate;
PubChem CID	9873581;
ChemSpider	8049270;
Chemical and physical data
Formula	C33H43Cl2NO5
Molar mass	604.609 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CC5=CC=C(C=C5)N(CCCl)CCCl)O)C;
	InChI InChI=1S/C33H43Cl2NO5/c1-31-12-9-25(37)20-23(31)5-8-26-27(31)10-13-32(2)28(26)11-14-33(32,40)29(38)21-41-30(39)19-22-3-6-24(7-4-22)36(17-15-34)18-16-35/h3-4,6-7,20,26-28,40H,5,8-19,21H2,1-2H3/t26-,27+,28+,31+,32+,33+/m1/s1; Key:PHIDEGNDCDIEQX-LNPWAVATSA-N;

Cortifen, also known as cortiphen or kortifen, as well as fencoron, is a synthetic glucocorticoid corticosteroid and cytostatic antineoplastic agent which was developed in Russia for potential treatment of tumors.[1][2][3] It is a hydrophobic chlorphenacyl nitrogen mustard ester of 11-deoxycortisol (cortodoxone).[1][2][3][4]

References

Lagova ND, Kiselev VI, Kurdiumova KN, Sof'ina ZP, Shkodinskaia EN (1989). "[Experimental study of the antitumor properties and mechanism of action of kortifen]". Vopr Onkol (in Russian). 35 (4): 450–6. PMID 2728387.
Oborotov, A. V.; Smirnova, Z. S.; Klochkova, T. I.; Arzamastsev, A. P. (1999). "Biopharmaceutical investigation of a new medicinal form of the antitumor drug cortifen". Pharmaceutical Chemistry Journal. 33 (10): 540–542. doi:10.1007/BF02508377. ISSN 0091-150X.
Smirnova, Z. S.; Rodionova, Yu. V.; Khalanskii, A. S.; Gershtein, E. S.; Gerasimova, G. K. (1999). "Dependence of antitumor effect of hormonal cytostatic cortifen on expression of glucocorticoid receptors in brain tumor cells". Bulletin of Experimental Biology and Medicine. 127 (3): 299–300. doi:10.1007/BF02433363. ISSN 0007-4888.
Oborotova NA, Smirnova ZS, Polozkova ZS, Baryshnikov AIu (2002). "[Pharmacological aspects in the development of liposomal medicinal preparations for the internal injection of hydrophobic cytostatics]". Vestn. Akad. Med. Nauk SSSR (in Russian) (1): 42–5. PMID 11882971.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.